Literature DB >> 1955719

Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A.

P Whitaker-Dowling1, H F Maassab, J S Youngner.   

Abstract

The attenuated cold-adapted strain of influenza A virus that is a candidate live-virus vaccine suppressed clinical disease in ferrets when given simultaneously with a virulent epidemic strain of influenza A virus. The cold-adapted virus effectively prevented disease, even when the epidemic strain was of a different subtype than the attenuated virus. In this case, ferrets given a mixed inoculum produced antibody to both subtypes in the absence of clinical disease, indicating that both viruses are replicating in the respiratory tract. These findings suggest the possibility of the development of a novel class of antivirals for influenza, namely a live virus that is a dominant-negative attenuated mutant that interferes with the replication of epidemic strains of virus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955719     DOI: 10.1093/infdis/164.6.1200

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Authors:  Pedro A Piedra; Manjusha J Gaglani; Mark Riggs; Gayla Herschler; Charles Fewlass; Matt Watts; Claudia Kozinetz; Colin Hessel; W Paul Glezen
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

2.  A vesiculovirus showing a steepened transcription gradient and dominant trans-repression of virus transcription.

Authors:  Erin N Hodges; Bianca S Heinrich; John H Connor
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

Review 3.  Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections.

Authors:  Sang-Uk Seo; Baik-Lin Seong
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

4.  Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans.

Authors:  J S Youngner; J J Treanor; R F Betts; P Whitaker-Dowling
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

5.  Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

6.  Interference is controlled by segment 2 and possibly by segment 8 of the nondefective interfering influenza virus variant A/FM/1/47-MA.

Authors:  E G Brown; C F Dimock; K Hannah
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain.

Authors:  T Laskus; L F Wang; M Radkowski; H Vargas; M Nowicki; J Wilkinson; J Rakela
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.